Liquid Biopsy Market - By Biomarkers (Circulating Tumor Cells [CTC], Circulating Tumor DNA [ctDNA]), By Product (Kits & Reagents, Assay & Panels), By Application (Lung Cancer, Breast Cancer, Colorectal cancer, Prostate Cancer) & Forecast, 2021-2027

Liquid Biopsy Market Size

Liquid Biopsy Market size exceeded USD 1.2 billion in 2020 and is anticipated to grow at a CAGR of over 29.7% between 2021 and 2027. Growing awareness regarding causes and diagnosis of cancer with several awareness campaigns will contribute to the demand for liquid biopsy in the coming years.
 

Liquid Biopsy Market Trends

Increasing preference for non-invasive technologies in disease diagnosis is poised to positively impact the adoption of liquid biopsy. Significant rise in the number of patients suffering from various cancers will create the substantial need for accurate diagnostic methods. Furthermore, growing number of ongoing clinical trials for the development of innovative solutions will accelerate the market expansion. Moreover, several advantages associated with liquid biopsy such as less invasive nature, improved precision and post-treatment monitoring will stimulate the industry demand.
 

The COVID-19 pandemic has moderately impacted the related product sales due to the disruption in healthcare services. The companies witnessed modest decline in the sales of reagents and kits in some countries. However, continued demand for instruments has reduced the intensity of negative impact. Additionally, with decline in number of COVID-19 cases, the sales of reagents are expected to grow at pre-pandemic pace.
 

Liquid Biopsy Market Analysis

Circulating tumor DNA segment in the liquid biopsy market valued at USD 550 million in 2020. Well-developed technology providing accuracy in tumor detection has significantly contributed to the industry revenue. High sensitivity in detection of early stage and advanced cancer, specifically breast cancer, will offer growth opportunities to the segment. In addition, the ctDNA biomarkers are used to study tumor progression among patients during clinical studies. Further, ctDNA provides an alternative pathway for the molecular profiling of tumor DNA in biopsy procedures.
 

Kits & reagents segment dominated more than 50% of the market share in 2020 led by the increasing acceptance of liquid biopsy in reference laboratories and research institutes. Several companies are involved in the development of innovative products to enhance the precision in liquid biopsy testing during diagnosis. Further, the integration and practice of liquid biopsy in clinical facilities will boost the product demand in the coming years.
 

Lung cancer segment is predicted to showcased 29.7% growth rate through 2027 impelled by the high incidence rate owing to the adoption of unhealthy lifestyle including smoking and tobacco consumption. In addition, the high risk of metastatic conditions among patients with lung cancer will support the acceptance of advanced biomarkers testing. The development of innovative tests specific to targets will further strengthen the segment expansion.

 

North America liquid biopsy market captured 31% of revenue share in 2020 on account of the availability of advanced products along with the presence of leading industry players. Further, rising incidence of cancer, faster adoption of advanced methods and highly advanced infrastructure will augment the regional growth. Accelerating demand for non-invasive disease diagnosis and continuous product launches with high focus on R&D by the market players will offer unprecedented growth opportunities to the industry.
 

Liquid Biopsy Market Share

Major companies operating in the liquid biopsy market are:

• F. Hoffmann-La Roche Ltd
• BIOCEPT Inc
• QIAGEN
• Myriad Genetics, Inc
• Guardant Health, Inc
• Illumina, Inc
• Lucence health Inc 
• EPIGENOMICS AG.

These participants are adopting various growth strategies such as collaborations, acquisitions & mergers, partnerships, and product launches to gain competitive edge over others.

 

The liquid biopsy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027 for the following segments:

Click here to Buy Section of this Report

Market, By Biomarkers

• Circulating Tumor Cells (CTC)
• Circulating Tumor DNA (ctDNA)
• Others

Market, By Product

• Kits & Reagents
• Assay & Reagents
• Others

Market, By Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
  • Mexico
• Middle East & Africa
  • South Africa
  • Saudi Arabia